History

Developed by Theratechnologies, a Canadian biopharmaceutical company, under the code TH9507. It stabilizes natural GHRH against enzymatic breakdown, prompting the pituitary to release growth hormone. The FDA approved it as Egrifta on November 10, 2010, for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, based on Phase III trials showing roughly 15-18% visceral-fat reduction over 26 weeks. Reformulated versions followed: Egrifta SV (2019) and the newer Egrifta WR.

Tesamorelin, sold as Egrifta, is one of the few peptides in this space with genuine, FDA-grade human evidence behind it. The catch is that the evidence is almost entirely confined to one specific medical population, and a lot of how the compound is marketed elsewhere goes well beyond what those studies showed.

What it is

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Instead of being growth hormone itself, it prompts the pituitary gland to release the body’s own growth hormone in a more natural, pulsatile pattern, which in turn raises insulin-like growth factor-1 (IGF-1). It is given as a once-daily subcutaneous injection. The FDA first approved it in 2010 for reducing excess visceral (deep abdominal) fat in adults with HIV-associated lipodystrophy.

The claims

In its approved use, the claim is narrow and well supported: it reduces excess belly fat in people with HIV who have lipodystrophy. Outside that lane, tesamorelin is widely promoted for general fat loss, “anti-aging,” bodybuilding cuts, better sleep, and liver-fat reduction in the general population. These broader claims are where evidence and marketing diverge.

What the evidence actually shows

The approval rested on two large, well-conducted phase 3 randomized, placebo-controlled trials (LIPO-010 and CTR-1011, roughly 800 HIV patients combined). Tesamorelin produced a statistically significant reduction in visceral adipose tissue versus placebo — on the order of 15-18% — measured by CT scan over 26 weeks. Pooled analyses also show modest gains in lean mass and reductions in trunk fat and triglycerides. Importantly, the benefit reverses once the drug is stopped, so it is not a one-time fix. The label is explicit that it is not a weight-loss drug and had no effect on overall body weight.

A separate, smaller randomized trial (Stanley et al., Lancet HIV, 2019; 61 participants, 12 months) found tesamorelin reduced liver fat and slowed fibrosis progression in people with HIV and fatty liver disease. That is a promising but small signal, and again it was studied in an HIV population.

What is missing: there are no comparable RCTs showing meaningful, durable benefit in healthy adults, athletes, or non-HIV individuals seeking cosmetic fat loss. The strong grade below applies to the studied population, not to the general public.

Legal and regulatory status

Tesamorelin is a prescription drug in the United States. The original Egrifta was followed by reformulations: Egrifta SV (the F4 formulation) and, most recently, Egrifta WR (the F8 formulation), which the FDA approved on March 25, 2025. Egrifta WR is still a daily injection, but its more concentrated formulation needs to be reconstituted only once a week rather than daily. All approvals remain limited to HIV-associated lipodystrophy; there is no approved indication for general weight or fat loss. For athletes, tesamorelin is banned at all times by the World Anti-Doping Agency as a growth hormone-releasing factor under category S2.

Safety

This is a real drug with real risks, documented in its FDA labeling. The most consistent concerns are elevated IGF-1 (which carries theoretical cancer concerns), glucose intolerance and worsening blood sugar, and fluid retention that can present as swelling, joint pain, and carpal tunnel syndrome. Injection-site reactions are common. It is contraindicated in pregnancy, in people with active cancer, and in those with disruption of the hypothalamic-pituitary axis; its long-term cardiovascular safety is not established. Compounded or research-grade “gray market” tesamorelin adds further unknowns around purity and dosing. None of this is medical advice.

Bottom line

For its approved use — visceral fat in HIV-associated lipodystrophy — tesamorelin has solid randomized evidence and is one of the better-studied peptides available. For everything else it is sold for, the human data simply isn’t there, and the safety profile is not trivial. Judge it by the population it was actually tested in.

Evidence grade: Strong human (for HIV-associated lipodystrophy only; no comparable evidence in the general population).

Tesamorelin (Egrifta): An Evidence-Graded Profile